Stockreport

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF ? Q4 2025 Unaudited Net Revenue of Approximately $127 million ? ? FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ? ? Expects Q4 Adjusted EBITDA [Read more]